Crossmark

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

Crossref DOI link: https://doi.org/10.14283/jpad.2022.30

Published Print: 2022-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Budd Haeberlein, Samantha

Aisen, P.S.

Barkhof, F.

Chalkias, S.

Chen, T.

Cohen, S.

Dent, G.

Hansson, O.

Harrison, K.

von Hehn, C.

Iwatsubo, T.

Mallinckrodt, C.

Mummery, C.J.

Muralidharan, K.K.

Nestorov, I.

Nisenbaum, L.

Rajagovindan, R.

Skordos, L.

Tian, Y.

van Dyck, C.H.

Vellas, B.

Wu, S.

Zhu, Y.

Sandrock, A.
License Information

Text and Data Mining valid from 2022-04-01

Text and Data Mining valid from 2022-04-01

Version of Record valid from 2022-03-18
More Information

This article is maintained by: Elsevier

Article Title: Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

Journal Title: The Journal of Prevention of Alzheimer's Disease

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jpad.2022.30

Content Type: article

Copyright: Copyright © 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS